title: The efficacy of alendronate in wheelchair-bound patients: a 1-year prospective study.
abstract: The aim of the study was to establish the efficacy of 1-year alendronate treatment in 10 wheelchair-bound participants. In the study were included participants with z-score lower than -2.0 in one of three skeletal sites. Bone status was assessed using dual-energy X-ray absorptiometry at calcaneus and forearm and using quantitative ultrasound at hand phalanges at baseline and after a year. Laboratory variables included serum carboxyterminal telopeptide of type I collagen (ICTP) and bone alkaline phosphatase. Mean values of bone measurements did not differ between baseline and follow-up, the mean value of ICTP nonsignificantly increased and bone alkaline phosphatase significantly dropped (P<0.01). No patient treated revealed the increase in three bone densitometric variables and only one showed a decrease in ICTP exceeding 40% of baseline value. Concluding, in wheelchair-bound participants short-term alendronate therapy does not reduce bone resorption and does not improve the skeletal status.
authors.affiliation: Metabolic Bone Diseases Unit, Department and Clinic of Internal Diseases, Diabetology and Nephrology, Zabrze, Medical University of Silesia in Katowice, Poland. osteolesna@poczta.onet.pl
authors.forename: Wojciech
authors.initials: W
authors.lastname: Pluskiewicz
authors.forename: Piotr
authors.initials: P
authors.lastname: Adamczyk
authors.forename: Przemysław
authors.initials: P
authors.lastname: Sawaryn
authors.forename: Anita
authors.initials: A
authors.lastname: Boroń
authors.forename: Maciej
authors.initials: M
authors.lastname: Misiołek
authors.forename: Krystyn
authors.initials: K
authors.lastname: Sosada
authors.forename: Bogna
authors.initials: B
authors.lastname: Drozdzowska
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D024042:Collagen Type I / Q000097:blood; D006233:Persons with Disabilities; D005260:Female; D006801:Humans; D007103:Immobilization; D008297:Male; D010455:Peptides / Q000097:blood; D011446:Prospective Studies; D016896:Treatment Outcome; D014910:Wheelchairs; D055815:Young Adult
chemical_list: D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; D019386:Alendronate